What is Inato?
Founded in 2015, Inato operates a sophisticated platform designed to bridge the gap between biopharmaceutical sponsors and clinical research sites. By leveraging data-driven insights, the company enables sponsors to significantly expand their patient pools, thereby reducing the time and cost associated with bringing life-saving therapies to market. In an industry where site selection and patient enrollment remain the primary bottlenecks for clinical success, Inato provides a critical infrastructure layer that enhances transparency and operational efficiency. The company's market position is defined by its ability to modernize traditional trial management through a scalable, software-as-a-service model that prioritizes site diversity and performance.
How much funding has Inato raised?
Inato has raised a total of $34M across 1 funding round:
Series A
$34M
Series A (2023): $34M with participation from Serena Ventures, Cathay Innovation, Fly Ventures, and The Obvious
Key Investors in Inato
Serena Ventures
A venture capital firm founded by Serena Williams that focuses on early-stage investments, prioritizing diverse leadership and companies with high-impact potential across various sectors including health and wellness.
Cathay Innovation
A global venture capital firm that connects multi-stage startups to a worldwide ecosystem, with a specific focus on technology-driven companies making a positive impact in healthcare and finance.
The Obvious
A full-service creative and design firm that specializes in transforming complex strategic ideas into visually compelling marketing and communication assets for diverse corporate clients.
What's next for Inato?
Following this major enterprise-level funding, Inato is expected to focus on deepening its technological capabilities and expanding its footprint within the global biopharmaceutical ecosystem. The strategic allocation of this capital will likely support the enhancement of its proprietary matching algorithms and the expansion of its network of research sites. As the clinical trial industry continues to shift toward decentralized and patient-centric models, Inato is poised to play a pivotal role in facilitating more inclusive and efficient research outcomes. The firm's trajectory suggests a transition from a specialized niche player to a foundational partner for large-scale pharmaceutical enterprises seeking to optimize their R&D investments.
See full Inato company page
